Navigation Links
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
Date:8/25/2009

resident of Research and Development at Amgen. "In contrast to a recent, smaller study of ESAs in a similar patient population, TREAT did not show a statistically significant adverse effect on all-cause mortality or cardiovascular morbidity when patients were treated to a hemoglobin target of 13 g/dL. We continue to believe that ESAs have a favorable benefit:risk profile when used according to the approved label."

Currently, Aranesp is indicated for the treatment of anemia in patients with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis. The approved label for Aranesp recommends individualizing dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. TREAT studied uses for Aranesp in which it is not approved.

TREAT Study Design

TREAT was an international, Phase 3, randomized, double-blind, placebo-controlled study of 4,038 chronic kidney disease (CKD) patients with type-2 diabetes and anemia. It is the largest study of ESA use in CKD patients to date. Patients enrolled in the study were randomized in a one-to-one ratio to receive either treatment with Aranesp to a target hemoglobin of 13 g/dL or placebo. Due to the increased risk of negative outcomes associated with low hemoglobin levels, patients in the control arm whose hemoglobin fell below 9 g/dL were given Aranesp until their hemoglobin level was 9 g/dL. Investigators were blinded to this intervention.

TREAT had two primary endpoints. The first evaluated time to all-cause mortality or cardiovascular morbidity including heart attack (myocardial infarction), congestive heart failure, hospitalization for angina (myocardial ischemia), or stroke (cerebrovascular accident). The second primary endpoint evaluated time to all-cause mortality or chronic dialysis. TREAT was not designed to determine the appropriate hemoglobin target in this patient population.

For
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
2. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
3. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Medarex to Receive Milestone Payment from Amgen
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... COLUMBUS, Ohio , Aug. 19, 2014 ... Ohio medical device company, announced today that ... FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan ... Corporation is also the exclusive distributor for Karl Storz ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... ANGELES, Jan. 13, 2011 UBM Canon and ... webinar to its webcast series on The Fundamentals of ... on Advanced Assay Technologies and Development Methods ... experts in the industry.   (Logo:   ...
... 13, 2011 CareGiver remote instrument support has expanded ... Medical System, Inc. ("VMSI") is the leading innovator in ... 5 years of success on the SYMPHONY H&E slide ... BenchMark ULTRA, strengthening the integration of the SYMPHONY and ...
Cached Medicine Technology:Advanced Assay Technologies and Development Methods 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... 20, 2014 One Call Alert expands its ... of ResCube, a fully-mobile wearable device that connects customers to ... button, 24 hours a day, 365 days a year. , ... cross country. It operates on the T-Mobile nationwide network like ... in to work. , Like with the other One Call ...
(Date:8/20/2014)... at the Universities of Manchester and Auckland suggest that both ... mechanism. , The findings, published today in the ... or type-1 diabetes and type-2 diabetes are both caused by ... , The results, based on 20 years, work ... both be slowed down and potentially reversed by medicines that ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
(Date:8/20/2014)... 20, 2014 Today, Zane Benefits, the ... open enrollment for 2015. , According to Zane Benefits, ... in November, employees are encouraged to start thinking about ... 2015, the open enrollment period will run from November ... 2015 individuals can purchase a new individual health insurance ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... , , WESTBURY, N.Y., July ... in the Ophthalmic Consultants of Long Island (OCLI) practice will perform ... of sight to those who have lost some or all of ... Cataract USA program, is offering this outpatient surgical procedure to residents ...
... , , , HOUSTON, ... , , If you would like to learn ... Texas Health Institute as they host a morning-long forum on "Building a Federal ... The event will be held at St. Joseph Medical Center, 1401 St. ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... financial results for the second quarter ended June 30, 2009 on ... , , NxStage will also host ... 5, 2009 to discuss its second quarter financial results. To listen ...
... , , WALTHAM, Mass., ... and advisory firms focusing on pharmaceutical and healthcare issues, finds that ... million in 2008 to more than $315 million in 2013. The ... Humira and Schering-Plough,s Remicade which recorded sales of $50 million and ...
... , , BANNOCKBURN, Ill., July ... in the United States(1). Yet it,s often not until the untimely passing ... or Tim Russert - that the issue is brought to the forefront ... heightened focus on heart health, a recent survey(2) uncovered that only 14 ...
... on intelligence tests at age 5 , MONDAY, July ... of a common airborne pollutant compound seems to threaten ... , The finding is based on the experience of ... City area. Specifically, it indicates that high prenatal exposure ...
Cached Medicine News:Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 3Health News:Building a Federal Health Board - Impact on Texas 2Health News:NxStage to Report Second Quarter 2009 Financial Results 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Exposure to Common Pollutant in Womb Might Lower IQ 2Health News:Exposure to Common Pollutant in Womb Might Lower IQ 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: